Search results for "03 medical and health sciences"

showing 10 items of 33400 documents

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct

Polyphenols and Pharmacological Screening of a Monarda fistulosa L. dry Extract Based on a Hydrodistilled Residue By-Product

2021

This study aimed to determine the composition and content of polyphenols in the dry extract obtained from the hydrodistilled residue by-product of the wild bergamot (Monarda fistulosa L., Lamiaceae Martinov family) herb (MFDE) and to evaluate its safety and pharmacological properties. The total phenolic content (TPC) in the MFDE was 120.64 mg GAE/g. The high-performance liquid chromatography (HPLC) analysis showed the presence of a plethora of phenolic compounds, including hydroxycinnamic acids and flavone derivatives in the MFDE, with rosmarinic acid and luteolin-7-O-glucoside being the main components. With an IC50 value of 0.285 mg/mL, it was found to be a strong DPPH radical scavenger. …

safetyDPPHRM1-950phenolic compoundsMonarda fistulosa01 natural sciencesHigh-performance liquid chromatographywild bergamot03 medical and health scienceschemistry.chemical_compound0302 clinical medicineantiradical activityPharmacology (medical)anti-inflammatory activityanalgesic activityOriginal ResearchPharmacologyResidue (complex analysis)biologyTraditional medicine010405 organic chemistryRosmarinic acidbiology.organism_classificationAcute toxicity0104 chemical scienceschemistryherbPolyphenol030220 oncology & carcinogenesispostdistillation wasteLamiaceaeTherapeutics. PharmacologyFrontiers in Pharmacology
researchProduct

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

2020

Funding: Transgène; International audience; Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase and domains of core and surface antigen and has shown immunogenicity and antiviral effects in mice. We performed a phase 1 clinical trial to assess safety and explore immunogenicity and early efficacy of TG1050 in CHB patients. This randomized, double blind, placebo-controlled study included two sequential phases: one single dose cohort (SD, n = 12) and one …

safetyHBsAg030231 tropical medicineImmunologyPlacebo-controlled studyPhases of clinical researchSciences du Vivant [q-bio]/Médecine humaine et pathologieimmunogenicityPlaceboAntiviral AgentsAdenoviridae03 medical and health sciencesMice0302 clinical medicineHepatitis B ChronicImmunogenicity VaccinevaccineImmunology and AllergyMedicineAnimalsHumans030212 general & internal medicineAdverse effectPharmacologyVaccinesHepatitis B Surface Antigens[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryELISPOTImmunogenicitychronicityimmuno-therapyHepatitis Bmedicine.diseaseHepatitis B3. Good healthImmunologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyResearch Paper
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

2017

ObjectiveOur aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.MethodsWe conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI95%) were calculated.ResultsSix RCTs were eligible (mino…

safetymedicine.medical_specialtyefficacyMinocyclinePlacebometa-analysi03 medical and health sciences0302 clinical medicinesystematic reviewInternal medicineefficacy; meta-analysis; Minocycline; safety; schizophrenia; systematic review; Neurology (clinical); Psychiatry and Mental HealthMedicineHumansRandomized Controlled Trials as TopicPositive and Negative Syndrome Scalebusiness.industryMinocycline schizophrenia efficacy safety meta-analysis systematic reviewConfidence interval030227 psychiatryDiscontinuationAnti-Bacterial Agentsmeta-analysisschizophreniaTolerabilityStrictly standardized mean differencePsychiatry and Mental HealthMeta-analysisAdjunctive treatmentNeurology (clinical)business030217 neurology & neurosurgeryAntipsychotic Agents
researchProduct

Common variants at VRK2 and TCF4 conferring risk of schizophrenia

2011

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field. Common sequence variants have recently joined rare structural polymorphisms as genetic factors with strong evidence for association with schizophrenia. Here we extend our previous genome-wide association study and meta-analysis (totalling 7 946 cases and 19 036 controls) by examining an expanded set of variants using an enlarged follow-up sample (up to 10 260 cases and 23 500 controls). In addition to previously reported alleles in the major histocompatibility complex region, near neurogranin (NRGN) and in an intron of transcription factor 4 (TCF4), we find two novel variants show…

schizophrenia; sequence variants; TCF4Genome-wide association studyTranscription Factor 40302 clinical medicineVRK2 protein humanPolymorphism (computer science)Genotypegenetics [Schizophrenia]NeurograninGenetics (clinical)Schizophrenia; Genotype; Risk; Alleles; Polymorphism Single Nucleotide; Transcription Factors; Humans; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Genetic Predisposition to Disease; Protein-Serine-Threonine Kinases; Genome-Wide Association StudyGenetics0303 health sciencesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsAssociation Studies ArticlesSingle NucleotideGeneral MedicineTCF4genetics [Transcription Factors]Protein-Serine-Threonine Kinases3. Good healthJRiskGenotypeProtein Serine-Threonine KinasesBiologyPolymorphism Single Nucleotidegenetics [Protein-Serine-Threonine Kinases]Molecular epidemiology [NCEBP 1]03 medical and health sciencesddc:570GeneticsHumansGenetic Predisposition to DiseasePolymorphismAllelegenetics [Basic Helix-Loop-Helix Leucine Zipper Transcription Factors]Settore MED/25 - PsichiatriaMolecular BiologyAllelesTCF4Molecular epidemiology Aetiology screening and detection [NCEBP 1]030304 developmental biologysequence variantsIntronOdds ratioMolecular biologySchizophreniaTCF4 protein human030217 neurology & neurosurgeryGenome-Wide Association StudyTranscription Factors
researchProduct

Un football des champs et un football des villes : analyse géographique du service football dans un cadre régional

2006

National audience; Le football représente une des formes d'activités de loisir les mieux représentées en France. Au regard de la population concernée par la discipline, il est légitime de la qualifier de service. Cet article propose une lecture géographique de l'offre du service football (les clubs) et de la demande exprimée par les pratiquants. La spatialisation des composants de ce service sportif dans un cadre régional (la Franche-Comté) a pour objectif d'apporter des éléments de connaissance permettant d'ajuster au mieux l'offre des clubs à la demande sociale.

segmentation du marché[SHS.GEO] Humanities and Social Sciences/GeographyPhysical Therapy Sports Therapy and Rehabilitation030229 sport sciences[SHS.GEO]Humanities and Social Sciences/Geographyservice sportif[ SHS.GEO ] Humanities and Social Sciences/Geographygéographie03 medical and health sciences0302 clinical medicineaire de recrutementOrthopedics and Sports MedicineSocial Sciences (miscellaneous)analyse spatiale
researchProduct

The Joint Distribution Criterion and the Distance Tests for Selective Probabilistic Causality

2010

A general definition and a criterion (a necessary and sufficient condition) are formulated for an arbitrary set of external factors to selectively influence a corresponding set of random entities (generalized random variables, with values in arbitrary observation spaces), jointly distributed at every treatment (a set of factor values containing precisely one value of each factor). The random entities are selectively influenced by the corresponding factors if and only if the following condition, called the joint distribution criterion, is satisfied : there is a jointly distributed set of random entities, one entity for every value of every factor, such that every subset of this set that corr…

selective influenceComputer scienceGeneralizationlcsh:BF1-990Value (computer science)systems of random variablescomputer.software_genre050105 experimental psychologyCausality (physics)Set (abstract data type)03 medical and health sciences0302 clinical medicineJoint probability distributionHypothesis and TheoryPsychology0501 psychology and cognitive sciencesstochastically unrelatedGeneral PsychologyDiscrete mathematics05 social sciencesProbabilistic logicexternal factorsstochastic dependencejoint distributionlcsh:PsychologyProbabilistic causalitySum of normally distributed random variablesData miningcomputerRandom variable030217 neurology & neurosurgeryFrontiers in Psychology
researchProduct